3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
14
Stomach Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Esophageal Neoplasms
3
Neoplasms
2
Leukemia, Biphenotypic, Acute
2
Intestinal Neoplasms
2
Gastrointestinal Neoplasms
2
Gastrointestinal Diseases
2
Digestive System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Diseases
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Malignant Solid Tumour
1
Lymphoma, Non-Hodgkin
1
Intestinal Diseases
1
Endometrial Neoplasms
1
Digestive System Diseases
1
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
Levoleucovorin
×
Clear all
NCT06428409
2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled